Fondo Bibliografico Internacional Mayo 2005
2.- Hepatitis B.
Treatment alternatives for chronic hepatitis B virus infection:
a cost-effectiveness analysis. Kanwal F, Gralnek IM, Martin P, et al. Annals
of Internal Medicine 2005;142:821-31.
Coste-efectividad de los diferentes tratamientos
disponibles en la actualidad para el VHB.
Assessing the benefits and costs of new therapies for hepatitis
B virus infection. Owens DK, Black M. Annals of Internal Medicine 2005;142:863-4.
Editorial.
Short statement of the first European consensus conference
on the treatment of chronic hepatitis B and C in HIV co-infected patients.
Alberti A, Clumeck N, Collins S, el al. Journal of Hepatology 2005;42:615-24.
Documento de consenso.
Tenofovir in chronic hepatitis B. Del Poggio P, Jamoletti C, Zaccanelli M.
Hepatology 2005;41:1199-200.
Carta.
Effect of lamivudine therapy on the serum covalently closed-circular
(ccc) DNA of chronic hepatitis B infection. Yuen MF, Wong DK, Sum SS, Yuan
HJ, Yuen JC, Chan AO, Wong BC, Lai CL. American Journal of Gastroenterology
2005;100:1099-103.
Notable efecto de la lamivudina sobre el DNA circular
en la hepatitis crónica B.
New therapies for lamivudine-resistant hepatitis B infection.
Blendis L. Gastroenterology 2005;128:1521-2.
Comentario.
